Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and care and decorative cosmetics; and bottles and jars for spirits and food. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+49-211-618100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9,947
OptionableNot Optionable
Gerresheimer (ETR:GXI) Frequently Asked Questions
What is Gerresheimer's stock symbol?
Gerresheimer trades on the ETR under the ticker symbol "GXI."
What price target have analysts set for GXI?
12 equities research analysts have issued 1-year price objectives for Gerresheimer's shares. Their forecasts range from €49.50 to €88.00. On average, they expect Gerresheimer's share price to reach €69.77 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price. View Analyst Price Targets for Gerresheimer.
What is the consensus analysts' recommendation for Gerresheimer?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gerresheimer in the last year. There are currently 2 sell ratings, 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Gerresheimer.
Has Gerresheimer been receiving favorable news coverage?
Media headlines about GXI stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Gerresheimer earned a news impact score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Gerresheimer's key competitors?
Some companies that are related to Gerresheimer include Advanced Medical Solutions (AMS), Akers Biosciences (AKR), Ansell (ANN), ANSELL LTD/S (ANSLY), Bovie Medical (BVX), Bovie Medical (BVX), Clover (CLV), CONVATEC GRP PL/ADR (CNVVY), CRH Medical (CRHM), CRH Medical (CRH), Daxor (DXR), Enerplus (ERF), Essilor International Cmgn Gnl D Optq (EI), InfuSystem (INFU) and Iris BioTechnologies (IRSB).
Who are Gerresheimer's key executives?
Gerresheimer's management team includes the folowing people:
- Mr. Rainer Beaujean, CFO & Member of the Management Board (Age 51)
- Mr. Andreas Schutte, Member of the Management Board (Age 57)
- Ms. Katja Schnitzler, Group Director of Bus. Excellence & Continuous Improvement and Member of the Supervisory Board (Age 38)
- Mr. Dietmar Siemssen, CEO & Member of Management Board (Age 56)
- Dr. Lukas Burkhardt, Member of Management Board (Age 40)
What is Gerresheimer's stock price today?
One share of GXI stock can currently be purchased for approximately €60.40.
What is Gerresheimer's official website?
How can I contact Gerresheimer?
Gerresheimer's mailing address is Klaus-Bungert-Strasse 4, DUESSELDORF, 40468, Germany. The company can be reached via phone at +49-211-618100.
MarketBeat Community Rating for Gerresheimer (ETR GXI)
MarketBeat's community ratings are surveys of what our community members think about Gerresheimer and other stocks. Vote "Outperform" if you believe GXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
